IceCure Medical (ICCM) Stock Analysis & Winston Score

IceCure Medical is an Israeli medical device company that makes a system for destroying tumors using extreme cold — a process called cryoablation. Its main product, ProSense, uses liquid nitrogen to freeze and kill small tumors inside the body, often without major surgery. The technology is used by doctors to treat breast cancer and other solid tumors, targeting hospitals and cancer treatment centers as its primary customers. The company earns revenue by selling its ProSense systems and the disposable probes used during each procedure, creating a recurring consumables stream alongside hardware sales. IceCure operates primarily in the United States, Europe, and Asia, but remains a small commercial-stage company with a very limited revenue base — reflected in its deeply negative operating margins. The key growth driver is expanding clinical adoption and gaining broader insurance reimbursement coverage, while the main risk is that larger, well-funded competitors already offer competing ablation technologies, making it difficult to win market share.